The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis

References

• Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164:1523–5.
   PubMed Web of Science ®Google Scholar
• Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A, Cancer statistics, CA Cancer J Clin. 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63:1059–71.
   PubMed Web of Science ®Google Scholar
• Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinarytract: surgical approach and prognostic factors. Eur Urol. 2008;53:720–31.
   PubMed Web of Science ®Google Scholar
• Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF, et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012;61:1069–70.
   PubMed Web of Science ®Google Scholar
• Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98:1181–6.
   PubMed Web of Science ®Google Scholar
• Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int. 2008;101:1368–74.
   PubMed Web of Science ®Google Scholar
• Li WM, Shen JT, Li CC, Ke HL, Wei YC, Wu WJ, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol. 2010;57:963–9.
   PubMed Web of Science ®Google Scholar
• Novara G, De Marco V, Dalpiaz O, Galfano A, Bouygues V, Gardiman M, et al. Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol. 2009;16:187–91.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, vander Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186–90.
   PubMed Web of Science ®Google Scholar
• Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol. 2010;183:56–61.
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Naito S, Kumazawa J, Ariyoshi A, Osada Y, Omoto T, et al. Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int J Urol. 2001;8:212–6.
   PubMed Web of Science ®Google Scholar
• Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013;31:1422–7.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996;17:1–12.
   PubMedGoogle Scholar
• Athanasiou T, Al-Ruzzeh S, Kumar P, Crossman MC, Amrani M, Pepper JR, et al. Off-pump myocardial revascularization is associated with less incidence of stroke in elderly patients. Ann Thorac Surg. 2004;77:745–53.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, Version 5.0.2; [updated September 2009]. The Cochrane Collaboration. http://cochrane.org/resources/hand book/ 2009.
   Google Scholar
• O'Brien T, Ray E, Singh R, Coker B, Beard R. British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol. 2011;60:703–10.
   Google Scholar
• Nagashima M, Araki A, Yanagisawa M, Komiya A, Takano T, Murakami T, et al. Effect of prophylactic intravesical instillation of pirarubicin to prevent recurrent bladder tumors following nephroureterectomy for upper urinary tract cancer. Hinyokika Kiyo. 2013;59:213–6.
   PubMedGoogle Scholar
• Kudoh T, Motomura F, Saitoh F, Kogawa T, Suzuki T. Prophylactic intravesical BCG for bladder tumor after surgery of upper tract urothelial carcinoma. Nihon Hinyokika Gakkai Zasshi. 1990;81:1857–60.
   PubMedGoogle Scholar
• Sakamoto N, Naito S, Kotoh S, Nakashima M, Nakamura M, Ueda T, et al. Recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract. Eur Urol. 1991;20:136–9.
   PubMed Web of Science ®Google Scholar
• Krogh J, Kvist E, Rye B. Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences. Br J Urol. 1991;67:32–6.
   PubMedGoogle Scholar
• Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet. 1993;342:1087–8.
   PubMed Web of Science ®Google Scholar
• Catto JW, Hartmann A, Stoehr R, Bolderson E, Rehman I, Rosario DJ. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol. 2006;175:2323–30.
   PubMed Web of Science ®Google Scholar
• Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer. 2002;101:1–6.
   PubMed Web of Science ®Google Scholar
• Harris AL, Neal DE. Bladder cancer: field versus clonal origin. N Engl J Med. 1992;326:759–61.
   PubMed Web of Science ®Google Scholar
• Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS. Bladder cancer after man-aging upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int. 2005;96:1031–5.
   PubMed Web of Science ®Google Scholar
• Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer. 2003;98:1620–6.
   PubMed Web of Science ®Google Scholar
• Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, et al. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology. 2000;55:663–7.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology. 2005;65:279–83.
   PubMed Web of Science ®Google Scholar
• Mukamel E, Simon D, Edelman A, Konichezky M, Hadar H, Servadio C. Metachronous bladder tumors in patients with upper urinary tract transitional cell carcinoma. J Surg Oncol. 1994;57:187–90.
   PubMed Web of Science ®Google Scholar
• Kusuda Y, Miyake H, Terakawa T, Kondo Y, Miura T, Fujisawa M. Gender as a significant predictor of intravesical recurrence in patients with urothelial carcinoma of the upper urinary tract following nephroureterectomy. Urol Oncol. 2013;31:899–903.
   PubMed Web of Science ®Google Scholar
• Terakawa T, Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology. 2008;71:123–7.
   PubMed Web of Science ®Google Scholar
• Wu CF, Chang PL, Chen CS, Chuang CK, Weng HH, Pang ST. The outcome of patients on dialysis with upper urinary tract transitional cell carcinoma. J Urol. 2006;176:477–81.
   PubMed Web of Science ®Google Scholar
• Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54:1127–34.
   PubMed Web of Science ®Google Scholar
• Gill IS, Sung GT, Hobart MG, Savage SJ, Meraney AM, Schweizer DK, et al. Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: the Cleveland Clinic experience. J Urol. 2000;164:1513–22.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Ono Y, Hattori R, Gotoh M, Kamihira O, Ohshima S. Retroperitoneoscopic nephroureterectomy for transitional cell carcinoma of the renal pelvis and ureter: Nagoya experience. Urology. 2003;61:533–8.
   PubMed Web of Science ®Google Scholar
• Kume H, Teramoto S, Tomita K, Nishimatsu H, Takahashi S, Takeuchi T, et al. Bladder recurrence of upper urinary tract cancer after laparoscopic surgery. J Surg Oncol. 2006;93:318–22.
   PubMed Web of Science ®Google Scholar
• Hattori R, Yoshino Y, Gotoh M, Katoh M, Kamihira O, Ono Y. Laparoscopic nephroureterectomy for transitional cell carcinoma of renal pelvis and ureter: Nagoya experience. Urology. 2006;67:701–5.
   PubMed Web of Science ®Google Scholar